Novartis' Cosentyx keeps up the good clearance through Year 4: Study

Novartis HQ cropped

Novartis’ Cosentyx has a head start on the next-gen psoriasis pack, but the company is still gunning to build its lead before a raft of new competitors arrive. And now, the Swiss drugmaker has some long-term data in hand that could help it on that quest.

Over the weekend, the pharma giant unveiled results showing that its psoriasis star could deliver high--and long-lasting--skin clearance in moderate-to-severe psoriasis patients over four years of therapy. 68.5% of patients in the study achieved clear or almost clear skin at the Year 1 mark, and that rate holds steady, holding at 66.4% at Year 4.

And those whose skin cleared completely on Cosentyx--43.8% of patients--got to keep enjoying that status, too, with the rate staying put at 43.5% at Year 4.

Since Novartis won approval for Cosentyx in January 2015, the company hasn’t slowed down with the med. The newcomer racked up $261 million in 2015 after launching in February, and early this year, it snagged a pair of new indications--psoriatic arthritis and ankylosing spondylitis--that’ll help pad that total for this year.

Still, though, Cosentyx will be far from alone in any of those disease areas. In psoriasis, Eli Lilly launched new-age rival Taltz earlier this year, and others aren’t far behind. Valeant is currently waiting for an FDA decision after an advisory panel backed its candidate brodalumab, and Johnson & Johnson over the weekend rolled out data showing its prospect guselkumab had beaten out AbbVie inflammatory giant Humira in a head-to-head study.

And in psoriatic arthritis, Pfizer’s Xeljanz for one is gearing up to provide a challenge. Companies including J&J--which makes blockbuster Stelara--could give Novartis a run for its money in ankylosing spondylitis, too, research and consulting firm GlobalData predicted last year. 

- read Novartis' release

Related Articles:
J&J's next-gen psoriasis med tops Humira in head-to-head showdown
Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals
Analyst: J&J's Stelara to challenge Novartis in ankylosing spondylitis
Pfizer gives up on a pair of Xeljanz indications--and it may dump psoriasis, too


Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.